Atopic dermatitis

Niemeier, V.; Kupfer, Jörg; Schill, Wolf‐Bernhard; Gieler, Uwe

doi:10.1080/09546630510027895

Cited by 9 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of potential side-effects, topical glucocorticoids are used primarily to control acute exacerbations of AD. 16 Obtaining medications in larger quantities can result in significant savings for patients. The potent fluorinated glucocorticoids should be avoided on the face, the genitalia and the intertriginous areas.…”

Section: Topical Glucocorticoidsmentioning

confidence: 99%

Management of Atopic Dermatitis

Boguniewicz¹,

Leung²

2016

Pediatric Allergy: Principles and Practice

View full text Add to dashboard Cite

Section: Topical Glucocorticoidsmentioning

confidence: 99%

Management of Atopic Dermatitis

Boguniewicz¹,

Leung²

2016

Pediatric Allergy: Principles and Practice

View full text Add to dashboard Cite

“…Only low‐potency ones should be used in infants and in areas such as the face, groin, and axillae. An adequate supply is essential for effective treatment and patient adherence to therapy, whereas patients often underestimate the appropriate quantity of topicals and emollients needed for a long‐term therapy (3). The role of the vehicle used to deliver the active ingredients is very important.…”

Section: Management and Treatment Of Atopic Dermatitismentioning

confidence: 99%

Buggiani¹,

Ricceri²,

Lotti³

2008

Dermatol Ther

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common dermatologic disease that can occur at different ages with different clinical manifestations. The etiologic factors and the pathogenetic pathways of AD have been thoroughly investigated but as often happens, something more has to be yet elucidated before the statement, that we possess the overall comprehension of the disease, could be considered the truth. Treatment of AD is often challenging, because of the chronic course of the disease and the fact that even the best of therapies is affected by adverse events, intolerances, or the possible occurrence of contraindications resulting from a sudden change in the overall health status of the patient (e.g., the onset of some comorbidities). Hence, the need to know "how, when, with what, and why" to treat AD patients with the many therapeutic modalities is now in the hands of the dermatologists.

show abstract

“…With extensive use, there is also the rare risk of systemic absorption, which may lead to suppression of the hypothalamic-pituitary-adrenal axis, adversely affecting the linear growth and bone density of children and adults, respectively. As a result, patients and caregivers often underutilize TCSs due to fear of side effects, termed “steroid phobia” [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

What’s New in Topicals for Atopic Dermatitis?

et al. 2022

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can have tremendous impact on quality of life for affected children and adults. First-line therapy for acute management of AD includes topical therapies such as corticosteroids, calcineurin inhibitors, and, more recently, the phosphodiesterase inhibitor crisaborole. Topical agents have remained the mainstay therapy for decades; however, there has been a longstanding need for topical therapies with high efficacy and low risk of adverse effects with long-term use. Given the ongoing advances in understanding the pathogenesis of AD, there are novel targets for pharmacological intervention. We are now in an unprecedented time with more than 40 topical treatments in the pipeline for AD in addition to many developments and treatments on the horizon. This review summarizes selected therapeutic topical agents in later phases of development that target various aspects in the pathogenesis of AD such as Janus kinase inhibition (ruxolitinib and delgocitinib), phosphodiesterase-4 inhibition (roflumilast and difamilast), aryl hydrocarbon modulation (tapinarof), and modulation of the microbiome. We also review novel targeted therapies that are in early phase clinical trials, including AMTX-100, BEN-2293, and PRN473. Preliminary findings on efficacy and tolerability of most of these agents are promising, but further studies are warranted to evaluate the long-term safety and efficacy of these novel agents against the current standard of care.

show abstract

Atopic dermatitis – topical therapy: Do patients apply much too little?

Abstract: Patients who applied the correct amount of the prednicarbate-containing preparations (not less than 90% of 0.5 g/dm(2)) to the areas of affected skin showed a significant improvement in SCORAD indices across the four measuring times.

Cited by 9 publications

References 28 publications

Management of Atopic Dermatitis

Management of Atopic Dermatitis

Atopic dermatitis

What’s New in Topicals for Atopic Dermatitis?

Contact Info

Product

Resources

About